Approved indications: Phytonadione injection is approved to treat coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity, including warfarin (coumarin) or indanedione‑induced hypoprothrombinemia, prophylaxis and treatment of vitamin K deficiency bleeding in newborns, and hypoprothrombinemia due to antibiotics, malabsorption (such as obstructive jaundice, biliary fistula, celiac disease, sprue, cystic fibrosis, intestinal resection, regional enteritis), or other drugs that impair vitamin K metabolism.

Common off‑label uses and evidence: Clinicians commonly use phytonadione off label to partially or fully reverse elevated INRs from warfarin in adults without major bleeding, and before urgent procedures, often alongside prothrombin complex concentrate (PCC) or fresh frozen plasma; these practices are supported by guideline‑level and observational evidence showing faster and more reliable INR correction when vitamin K is combined with PCC than with plasma alone.

Efficacy expectations and onset: After subcutaneous or slow intravenous dosing, INR and other clotting tests usually begin to improve within about 1–8 hours, with the speed depending on the dose, route, and how high the INR was to start; a single intramuscular neonatal dose (0.5–1 mg) prevents nearly all cases of classic and late vitamin K deficiency bleeding, reducing the incidence of late VKDB to less than about 1 in 100,000 infants compared with much higher rates without prophylaxis.

Comparison with related therapies: Phytonadione restores your own production of clotting factors but works more slowly than factor concentrates; four‑factor PCC or plasma can normalize INR within minutes, while vitamin K sustains the effect over the next days by allowing new clotting factors to be synthesized, so they are typically used together for life‑threatening warfarin‑associated bleeding or emergency surgery.

General administration: Phytonadione injection is given only by a healthcare professional as a subcutaneous, intramuscular, or slow intravenous injection; the subcutaneous route is preferred, and if IV dosing is unavoidable it should be infused very slowly, typically not exceeding 1 mg per minute, with the dose tailored to the degree of hypoprothrombinemia and the urgency of reversal.

Typical adult dosing ranges (coagulation disorders): For warfarin or other vitamin K antagonist–induced hypoprothrombinemia in adults, common injectable doses are about 2.5–10 mg given subcutaneously, intramuscularly, or intravenously, with up to 25–50 mg sometimes used as a single dose in severe cases; for hypoprothrombinemia from other causes (such as antibiotic use or fat‑malabsorption disorders), doses of about 2.5–25 mg (occasionally up to 50 mg) are used, with follow‑up doses guided by repeat INR or prothrombin time and the clinical picture.

Neonatal prophylaxis and treatment: For prevention of vitamin K deficiency bleeding, term and preterm newborns are typically given a single 0.5–1 mg dose within the first hours after birth, usually intramuscularly in the thigh; for treatment of established vitamin K deficiency bleeding in neonates, a 1 mg subcutaneous or intramuscular dose is commonly used, with possible adjustment if the mother was on vitamin K antagonists.

Monitoring and titration: Because the effect is not immediate, clinicians re‑check INR or prothrombin time—often within about 6–8 hours—to determine whether more phytonadione or adjunctive therapies (such as PCC or plasma) are needed, and they generally use the lowest effective dose to avoid prolonged resistance to warfarin or other vitamin K antagonists.

Special dosing instructions: The drug is usually diluted in compatible IV fluids for infusion and protected from light until use; benzyl‑alcohol–free diluents and formulations are preferred in neonates and young infants, and parenteral solutions are visually inspected for discoloration or particles before administration.

Missed doses and overdose: Because injections are typically given in hospitals or clinics, missed doses are uncommon, but if a scheduled dose is delayed or missed the prescriber will decide whether and when to administer another dose based on current INR and bleeding risk; suspected overdose or accidental extra dosing—especially in a child—should prompt immediate contact with a poison control center (1‑800‑222‑1222 in the U.S.) or emergency services.

Common side effects: The most frequent reactions are mild and include injection‑site pain, redness or swelling, flushing or a warm sensation, sweating, dizziness, and temporary changes in taste; these usually occur soon after the injection and resolve on their own.

Serious or rare adverse effects: Rarely, severe hypersensitivity or anaphylactic reactions have occurred, especially with intravenous or intramuscular injection, and can include rash, hives, chest tightness, trouble breathing, low blood pressure, rapid heartbeat, blue lips or skin, or collapse—these require immediate emergency care; delayed skin reactions (eczema‑like or scleroderma‑like patches) and liver‑related effects such as hyperbilirubinemia or jaundice have also been reported.

Route‑related precautions: Because fatal and life‑threatening anaphylactic reactions have been reported with IV and IM use, the subcutaneous route is preferred whenever feasible, and if IV administration is necessary it must be given very slowly (not more than about 1 mg per minute) with close monitoring during and shortly after the infusion.

Pregnancy, breastfeeding, and age‑related cautions: Experience in pregnancy has not shown a clear pattern of birth defects, but animal reproduction data are lacking, so use during pregnancy is reserved for clear need and preservative‑free formulations are preferred; phytonadione appears in breast milk but is generally considered compatible with breastfeeding when needed, again preferring benzyl‑alcohol–free products; in neonates and especially premature infants, excessive doses and products containing benzyl alcohol can cause hemolysis, jaundice, or "gasping syndrome," so recommended neonatal doses must not be exceeded and preservative‑free formulations are used.

Kidney, liver disease, and other precautions: In severe liver disease, lack of response to phytonadione often reflects underlying hepatic failure rather than drug failure, so repeated large doses are not recommended; as with other reversal agents, reversing anticoagulation in patients at high thrombotic risk should be balanced against the increased risk of clotting once vitamin K has taken effect.

Relative safety compared with alternatives: Compared with plasma or PCC, phytonadione alone does not expose patients to blood‑product risks such as volume overload or transfusion reactions, but it also acts more slowly and carries a small risk of severe injection‑related hypersensitivity that is minimized by using the subcutaneous route and slow IV infusion when needed.

Reporting side effects and safety updates: Patients and caregivers in the United States can report suspected side effects to the FDA’s MedWatch program online or by calling 1‑800‑332‑1088, and can review current safety communications about phytonadione and other drugs on the FDA website.

Interactions with anticoagulants and other drugs: Phytonadione specifically counteracts the effect of vitamin K antagonist anticoagulants such as warfarin by restoring vitamin K–dependent clotting factor production, so it can cause temporary resistance to these drugs and may require higher anticoagulant doses or a switch to another agent such as heparin when anticoagulation is restarted; it does not reverse the effects of heparin or most direct oral anticoagulants.

Other medicines and supplements: Many antibiotics, salicylates, and some other drugs can cause or worsen vitamin K deficiency and are reasons phytonadione may be prescribed; conversely, large or frequent vitamin K doses (including high‑dose supplements or repeated injections) can make INR control with warfarin more difficult, so patients should not start or stop vitamin K–containing supplements without medical guidance and should always tell their clinicians about all prescription drugs, OTC medicines, and herbal products they use.

Food and alcohol interactions: Because this formulation is injected, short‑term dietary vitamin K intake (for example from leafy greens) has little effect on a single treatment dose, but for patients going back on warfarin after reversal, a consistent vitamin K–containing diet and avoidance of binge alcohol use remain important to maintain stable anticoagulation.

Conditions and co‑medications requiring caution: Use is cautious in patients with a history of severe allergy to phytonadione or other injectable emulsions, in neonates and young infants (due to risks of benzyl alcohol toxicity and bilirubin displacement), and in those where rapid reversal of anticoagulation could raise the risk of thrombosis (such as patients with mechanical heart valves or recent venous thromboembolism); in advanced liver failure, a poor response to phytonadione often indicates that the liver cannot synthesize clotting factors adequately, and repeated large doses are not helpful.

Monitoring needs: Patients receiving phytonadione for warfarin reversal or vitamin K deficiency typically have serial INR or prothrombin time measurements until clotting normalizes and then again as anticoagulation is restarted; clinicians also monitor for signs of allergic reactions during and after injection, and in neonates they watch for jaundice or other evidence of hemolysis or bilirubin elevation.

Q: What is phytonadione injection and what is it used for?
A: Phytonadione is an injectable form of vitamin K1 used to prevent and treat bleeding caused by low vitamin K–dependent clotting factors, including warfarin‑related over‑anticoagulation, vitamin K deficiency from illness or medicines, and vitamin K deficiency bleeding in newborns.

Q: How quickly does a dose of phytonadione start working?
A: After a subcutaneous or slow intravenous dose, blood‑clotting tests such as the INR usually begin to improve within a few hours, with full effect often seen between about 6 and 8 hours depending on the dose, the route, and how abnormal the INR was to start.

Q: Why do newborns get a vitamin K (phytonadione) shot at birth?
A: Babies are born with very low vitamin K stores and breast milk contains only small amounts, so a single injection of phytonadione shortly after birth protects them from vitamin K deficiency bleeding, which can otherwise cause life‑threatening intestinal or brain hemorrhage.

Q: Is phytonadione injection safe if I am pregnant or breastfeeding?
A: Available human experience has not shown a clear pattern of birth defects or problems in breastfed infants, but animal data are limited; when phytonadione is needed in pregnancy or lactation, clinicians generally choose the lowest effective dose and prefer preservative‑free products to avoid exposing the baby to benzyl alcohol.

Q: What are the most important risks I should watch for after receiving this medicine?
A: The main serious risk is a rare but potentially life‑threatening allergic or anaphylactic reaction, especially with IV or IM injection, so you should seek emergency care right away if you develop rash, hives, chest tightness, trouble breathing, sudden dizziness or fainting, or swelling of the face, lips, tongue, or throat.

Q: Will this medicine interfere with my warfarin or other blood thinner long term?
A: A treatment dose of phytonadione will lower your INR and can make you temporarily resistant to warfarin and similar vitamin K antagonists, so if long‑term anticoagulation is needed your prescriber will adjust or briefly change your blood thinner and monitor your INR closely until it restabilizes.

Storage: Store phytonadione injection at room temperature (about 68–77°F / 20–25°C), in its original carton, tightly closed, and protected from light; do not freeze, and keep it out of reach of children and pets.

Handling of single‑use vials or syringes: Any portion left in a single‑use container after a dose should be discarded and not saved for later use.

Disposal: Do not throw loose needles or syringes into household trash and do not flush this medicine down the toilet; instead, use a community drug take‑back program or follow pharmacist or local waste‑disposal guidance for sharps and unused medication.